McNeil pulls another 2.5M packages of Tylenol drug

The problems at McNeil Consumer Healthcare's troubled manufacturing plants continue to haunt Johnson & Johnson. The company has announced yet another recall of a Tylenol product made either at the now-shuttered Fort Washington, PA, plant or at another problem facility in Puerto Rico.

The company is pulling 2.5 million packages of Tylenol Cold Multi-Symptom Nighttime Rapid Release Gelcaps after discovering that certain capsules contained higher-than-expected levels of chlorpheniramine ammonio acetate (CPAA), the Wall Street Journal Health Blog reports. CPAA is formed by the combination of two ingredients in the product; it hasn't been linked to any health problems.

As the Philadelphia Inquirer notes, this recall is the fifth by McNeil this year. Most of the products pulled were Tylenol-branded meds, but some Benadryl and Sudafed products were also recalled. J&J units also recalled a couple of prescription drugs--Risperdal and Prezista--as well as several other products, including insulin-pump cartridges and surgical sutures.

J&J has lost hundreds of millions in sales from the McNeil recalls, and it's still working to fix all of the manufacturing problems uncovered by the FDA. The company entered into a consent decree in March with the agency, covering operations in Fort Washington and Lancaster, PA, as well as Las Piedras, Puerto Rico.

- see the story from the Health Blog
- check out the Dow Jones news
- get more from the Inquirer

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.